Question to the Department of Health and Social Care:

To ask Her Majesty's Government what assessment they have made of the emergency use authorisation listed on 8 December 2021 of AstraZeneca's Evusheld for pre-exposure prophylaxis in (1) certain adults, and (2) children.

We are aware that the United States Food and Drug Administration (FDA) listed an emergency use authorisation for Evusheld in December 2021, which was revised on 24 February 2022. The FDA has modified their dosing regimen according to its available data and consider that a higher dose of Evusheld may be more likely to prevent infection by the Omicron subvariants BA.1 and BA.1.1 than the originally authorised Evusheld dose.

We continue to monitor emerging data for Evusheld and other treatments for applicability in the United Kingdom for prevalent variants and which patient groups could potentially benefit. Evusheld is not currently authorised in the UK.